EZ Biosystems

Executive Summary

EZ Biosystems is a US-based biotechnology company founded in 2017 that develops and commercializes next-generation transfection reagents under the Avalanche® brand. The company's products are designed to enable efficient gene delivery into difficult-to-transfect cells, including primary cells and various cell lines, serving academic, government, and biopharmaceutical researchers worldwide. Despite a niche focus on a critical enabling technology for cell and gene therapy research, EZ Biosystems remains at an early stage with no disclosed funding, valuation, or revenue metrics. The company operates in the diagnostics and infectious disease categories, but its core technology is broadly applicable across life science research. Given the lack of publicly available commercial traction or strategic milestones, the near-term outlook is uncertain, though the technology addresses a clear market need in gene delivery.

Upcoming Catalysts (preview)

• TBDExpansion of Avalanche product line with new formulations for hard-to-transfect primary cells50% success